Regeneron Pharmaceuticals: Sequencing Its Way To +30% Upside
May 03, 2018 at 07:05 AM EDT
Regeneron's stock price fall over the last 10 months is not supported by the numbers. With a broadening portfolio of drugs on the market, the company is set to prove to investors that it is not a one-trick pony.
